AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26.

To Date: 29/08/2026 The Manager Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001. Scrip Code: 544759, Scrip ID: GLPL, Sub: Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26. Dear Sir / Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the item 13 of Part –A, Schedule III of the Listing Regulations, we have attached herewith the proceedings of 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26 held on Saturday, August 29, 2026 at 04:00 P.M. and concluded at 05:05 P.M. For your information and record. Kindly acknowledge and oblige. Thanking you, Yours faithfully, For Goldline Pharmaceutical Limited Ruchi Sanket Modi Company Secretary cum Compliance Officer PROCEEDINGS OF THE 22ND ANNUAL GENERAL MEETING OF THE MEMBERS OF GOLDLINE PHARMACEUTICAL LIMITED HELD ON SATURDAY, 29TH AUGUST, 2026 AT 04:00 P.M. AT HOTEL AIRPORT CENTRE POINT, 131/1, ADJACENT TO AIRPORT, WARDHA ROAD, SOMALWADA, NAGPUR, MAHARASHTRA 440025 The 22nd Annual General Meeting (“AGM”) of the Goldline Pharmaceutical Limited (“the Company”) was held on Saturday, 29th August 2026 at 04:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025. Time of Commencement: 04:00 P.M Time of Conclusion: 05:05 P.M. 1. MEMBERS OF THE BOARD AND KEY MANAGERIAL PERSONNEL PRESENT: The following Directors and Key Managerial Personnel were present at the Meeting: 1. Mr. Amol Laxmikant Mujumdar – Chairman & Managing Director 2. Mr. Swapan Khandelwal – Whole-Time Director 3. Dr. Prashant Rahate – Non-Executive Director 4. Mr. Prashant Shrikrishna Karkare – Executive Director 5. Mr. Avinash Pandurang Ambulkar – Executive Director 6. Mrs. Dipti Sharad Bhusari – Chief Financial Officer 7. Mr. Mehul Hari Ranade – Independent Director 8. Mrs. Renuka Saurabh Borole – Independent Director 9. Ms. Shraddha Kiran Kulkarni – Independent Director 10. Ms. Ruchi Modi – Company Secretary & Compliance Officer 2. INVITEES The following invitees were present at the Meeting: 1. CA Nilesh Tiwari – Statutory Auditor (On Behalf of M/s. B Shroff & Co, Chartered Accountants) 2. CS Avinash Gandhewar – Secretarial Auditor & Scrutinizer (On Behalf of M/s. Avinash Gandhewar & Associates, Practicing Company Secretaries) 3. CS Kunal Dutt – Internal Auditor (On Behalf of M/s. Kunal Dutt & Associates, Practicing Company Secretaries) 3. MEMBERS Total 15 Members, including authorised representatives, attended the meeting at the venue. The requisite quorum being present, the Meeting was called to order. 4. WELCOME AND INTRODUCTION The meeting commenced with a welcome address by Mr. Kiran Durugkar, Anchor for the AGM, who welcomed the Members, Directors, senior management, auditors and other distinguished guests present at the meeting. The Anchor highlighted that the AGM was particularly significant as it was the first Annual General Meeting of the Company following the successful listing of its equity shares on the BSE SME Platform in May 2026. The members of the Board and senior management present on the dais were introduced to the Members. 5. FORMAL OPENING OF THE MEETING Thereafter, Ms. Ruchi Modi, Company Secretary & Compliance Officer, welcomed the Members and briefed them regarding the formal proceedings of the AGM. The Members were informed that the Notice convening the 22nd AGM, together with the Annual Report for the financial year ended 31st March 2026, had been circulated to the Members in accordance with the applicable provisions of the Companies Act, 2013 and other applicable regulatory requirements. The Company Secretary further informed the Members regarding the facility of remote e- voting provided by the Company. The Members were informed that the remote e-voting facility was made available from Tuesday, 25th August 2026 at 9:00 A.M. to Friday, 28th August 2026 at 5:00 P.M. It was further informed that Members who had already exercised their voting rights through remote e-voting could attend the AGM but would not be entitled to vote again at the meeting. Members who had not exercised their votes through remote e-voting were provided an opportunity to cast their votes through ballot paper during the AGM. The Company had appointed M/s. Avinash Gandhewar & Associates as Scrutinizer for scrutinizing the voting process and submitting the Scrutinizer’s Report. 6. FINANCIAL PERFORMANCE FOR FY 2025-26: Thereafter, Mr. Swapan Khandelwal, Whole-Time Director, addressed the Members and presented the financial performance and key financial highlights of the Company for the financial year 2025-26. The Members were informed that the Company’s Revenue from Operations and Other Income increased from ₹2,805.57 lakhs in FY 2024-25 to ₹3,119.88 lakhs in FY 2025-26. The Profit Before Tax increased from ₹385.84 lakhs to ₹538.54 lakhs, while Profit After Tax increased from ₹283.43 lakhs to ₹411.71 lakhs. The Earnings Per Share also improved from ₹4.11 to ₹5.97. The Whole-Time Director further apprised the Members about the Company’s business model, operational focus and priorities for FY 2026-27, including expansion of the customer base, strengthening of market presence, improvement in operational capabilities, adoption of technology, process optimisation and pursuit of sustainable and profitable growth. 7. BUSINESS JOURNEY, MARKET INSIGHTS AND FUTURE OUTLOOK: Thereafter, Mr. Prashant Karkare, Executive Director, addressed the Members and shared his perspective on the Company’s journey from market insights to market leadership. He apprised the Members about the competitive and evolving pharmaceutical market, the Company’s focus on strengthening its product portfolio, improving engagement with the medical fraternity, expanding geographical presence and strengthening its sales and marketing capabilities. He further stated that the Company would focus on developing meaningful and sustainable brands and exploring opportunities in specialty and super-specialty segments. The Members were also informed that the successful listing of the Company on the BSE SME Platform marked the beginning of a new phase of growth and greater responsibility towards all stakeholders. 8. ADDRESS BY THE CHAIRMAN & MANAGING DIRECTOR Thereafter, Mr. Amol Mujumdar, Chairman & Managing Director, addressed the Members. The Chairman & Managing Director welcomed the Members and expressed his appreciation for their continued trust and confidence in the Company. He highlighted the Company’s journey, its foundation in pharmaceutical expertise, customer relationships, quality products and long-term growth, and acknowledged the contribution of employees, customers, business partners, advisors, associates and shareholders. He further stated that the successful listing of the Company had strengthened its financial foundation and enhanced its visibility in the capital markets. The Chairman & Managing Director reiterated the Company’s commitment to transparency, corporate governance, regulatory compliance, responsible financial management and sustainable value creation. He thereafter placed before the Members the agenda items forming part of the 22nd AGM. 9. BUSINESS ITEMS / AGENDA The following items of business were placed before the Members for their consideration and approval: ORDINARY BUSINESS Item No. 1 – Adoption of Financial Statements To receive, consider and adopt the Standalone Audited Balance Sheet as at 31st March 2026, the Statement of Profit and Loss for the financial year ended on that date, the Cash Flow Statement, together with the Auditors’ Report and Directors’ Report thereon. Item No. 2 – Declaration of Dividend To declare dividend of ₹12/- per preference share of face value of ₹100/- each for the financial year 2025-26. Item No. 3 – Re-appointment of Director To re-appoint Mr. Prashan [Showing first 8,000 characters — download PDF for full document]